ライフサイエンスコーパス: beta-lactamase

1 ge, for a cryptic allosteric site in CTX-M-9 beta-lactamase.

2 effects of single amino acid InDels in TEM-1 beta-lactamase.

3 rug is only bactericidal after activation by beta-lactamase.

4 activity was not observed in strains without beta-lactamase.

5 rsely affecting bacteria that do not produce beta-lactamase.

6 ble point mutants of a single protein, TEM-1 beta-lactamase.

7 ctions between sequential mutations in TEM-1 beta-lactamase.

8 oducing an AmpC and 11 coproducing a metallo-beta-lactamase.

9 ssion for the beta-lactam resistance enzyme, beta-lactamase.

10 lla pneumoniae carbapenemase (KPC-2) class A beta-lactamase.

11 with isolates coproducing an AmpC or metallo-beta-lactamase.

12 90.1% of isolates that coproduced a metallo-beta-lactamase.

13 cylation rate compared with the common TEM-1 beta-lactamase.

14 apenem scaffold to avoid hydrolysis by KPC-2 beta-lactamase.

15 ion with MDR P. aeruginosa that lack metallo-beta-lactamases.

16 s in the contexts of hydrolysis by different beta-lactamases.

17 -binding proteins, or for the related serine beta-lactamases.

18 n bacterial cell walls and can be cleaved by beta-lactamases.

19 nems, and monobactams), by the production of beta-lactamases.

20 rried genes coding for extended-spectrum SHV beta-lactamases.

21 mases (ESBLs), AmpCs, K1, and broad-spectrum beta-lactamases.

22 e sensitive detection of clinically-relevant beta-lactamases.

23 um activity against class A, C, and D serine beta-lactamases.

24 ded-spectrum beta-lactamases (ESBL) and AmpC beta-lactamases.

25 overed inhibitors of serine and some metallo beta-lactamases.

26 domains or the structurally similar class D beta-lactamases.

27 ted antibiotics, including extended-spectrum beta-lactamases.

28 sistant to hydrolysis by all four classes of beta-lactamases.

29 f resistance genes, including those encoding beta-lactamases.

30 d resistance, specifically New Delhi metallo-beta-lactamase-1 (NDM-1).

31 moniae Carbapenemase-4 and New Delhi Metallo-beta-Lactamase-1 in the United States, recognition of th

32 obacteriaceae that produce extended-spectrum beta-lactamases (82.4% vs. 75.0%).

33 Two chromosomally encoded inducible beta-lactamases, a Pen-like class A and AmpC are produce

34 beta-lactamase activity in humans has been neglected, ev

35 revious studies have demonstrated that their beta-lactamase activity is comparable to those of well-k

36 adeoff: mutations that increase the enzyme's beta-lactamase activity tend to increase also its suscep

37 ence of the other MBLAC2 role as a bona fide beta-lactamase allows for reassessment of beta-lactams a

38 ompound in the library, docking against AmpC beta-lactamase (AmpC) and the D(4) dopamine receptor wer

39 ytoplasmic events that lead to expression of beta-lactamase, an antibiotic-resistance determinant.

40 ing endonuclease CPSF-73, containing metallo-beta-lactamase and beta-CASP domains and a cluster of co

41 Interestingly, in addition to the metalo-beta-lactamase and beta-CASP domains, RNase J of plants

42 ountries, and characterized the conjugative, beta-lactamase and cryptic plasmids.

43 ei were all ST106, and encoded for blaACT-15 beta-lactamase and fosfomycin resistance (fosA).

44 ction but also distinguishes between metallo-beta-lactamase and serine-carbapenemase production in P.

45 tically couple to metalloproteins related to beta-lactamases and nitric oxide reductases.

46 inhibit clinically relevant class A, C and D beta-lactamases and penicillin-binding proteins, resulti

47 between the inhibition efficacy of purified beta-lactamases and the potentiation of beta-lactam anti

48 esistant strains producing extended-spectrum beta-lactamases and/or carbapenemases.

49 determinants of beta-lactam resistance (e.g. beta-lactamase) and redox potential in Mtb.

50 hia coli (ESBL) (producing extended spectrum beta-lactamases) and Morganella morganii.

51 ense mutations in the Escherichia coli TEM-1 beta-lactamase antibiotic resistance gene using growth c

52 beta-Lactamases are a major threat to the clinical use o

53 The hydrolytic enzymes called beta-lactamases are responsible for a large proportion o

54 Finally, beta-lactamases are widely distributed, archaic, and hav

55 CTX-M beta-lactamases are widespread in Gram-negative bacteria

56 buting to AMR, including seven class A and C beta-lactamases as well as mutations in gyrA and parC re

57 gus Aspergillus niger, and the TEM-family of beta-lactamase associated with antibiotic resistance.

58 ctamase enzymes, carbapenemases or ampC type beta-lactamases, at least one of which was detected in m

59 relevant E. coli isolates expressing diverse beta-lactamases; bactericidal activity was not observed

60 The beta-Lactamase (BL) enzyme family is an important class

61 and were based on the absence or presence of beta-lactamase (bla) NDM, VIM, IMP, KPC, and OXA carbape

62 t competitive inhibition of the M. abscessus beta-lactamase, Bla(Mab), using a novel assay, which is

63 uberculosis (Mtb) expresses a broad-spectrum beta-lactamase (BlaC) that mediates resistance to one of

64 to carry the recently characterized metallo-beta-lactamase blaSPR-1 that, although not conferring hi

65 beta-Lactamases (BLs) able to hydrolyze beta-lactam anti

66 e beta-lactam antibiotic action by producing beta-lactamases (BLs), including carbapenemases, which a

67 m and a bicyclic boronate inhibit L2 (serine beta-lactamase) but not L1 (metallo beta-lactamase) from

68 n) shows stability to most extended spectrum beta-lactamases, but is considered inactive against Pseu

69 r ability to hydrolyze penicillins, emergent beta-lactamases can now confer resistance to other beta-

70 concentration, as shown by the treatment of beta-lactamase-carrying Escherichia coli with cefotaxime

71 lp unravel the ambiguity surrounding class A beta-lactamase catalysis, we have used ultrahigh-resolut

72 ance to beta-lactam antibiotics is via their beta-lactamase-catalyzed hydrolysis.

73 de into four classes; the active-site serine beta-lactamases (classes A, C and D) and the zinc-depend

74 c prodrug that combines ciprofloxacin with a beta-lactamase-cleavable motif.

75 sensitive and specific for the detection of beta-lactamase compared to the blaZ PCR results, whereas

76 m to trap the acyl-enzyme complex of class A beta-lactamase CTX-M-14 at varying pHs.

77 f the globally distributed extended-spectrum beta-lactamase CTX-M-15, and find three non-synonymous m

78 he reaction outcomes and mechanisms by which beta-lactamases degrade carbapenems are still not fully

79 viously overlooked in the well-studied TEM-1 beta-lactamase demonstrates the utility of exposons.

80 beta-Lactamases divide into four classes; the active-sit

81 rst product complexes for a wild-type serine beta-lactamase, elucidating the product release mechanis

82 isms were KPC (K. pneumoniae carbapenemases) beta-lactamases encoded by blaKPC2, blaKPC3, and blaKPC4

83 hage genome carrying only an f1 origin and a beta-lactamase-encoding (bla) antibiotic resistance gene

84 ay was performed on all isolates to identify beta-lactamase-encoding genes.

85 tance genes (ARGs), including those encoding beta-lactamase enzymes (BLA), which degrade commonly pre

86 echanism of action of the different types of beta-lactamase enzymes as a basis for inhibitor design a

87 er cryptic allosteric sites in two different beta-lactamase enzymes that are widespread sources of an

88 In Gram-negative bacteria, beta-lactamase enzymes that hydrolyze the amide bond of

89 gs could be explained by inhibitor-resistant beta-lactamase enzymes, carbapenemases or ampC type beta

90 2 and DHA-1) and class A (TEM-1 and CTX-M-2) beta-lactamase enzymes, respectively.

91 Gram-negative bacteria is the production of beta-lactamase enzymes.

92 ctrum inhibitors of both serine- and metallo-beta-lactamase enzymes.

93 counteract antibiotic resistance mediated by beta-lactamase enzymes.

94 he rapid rise in the number and diversity of beta-lactamases, enzymes that inactivate beta-lactams, a

95 Staphylococcus aureus and extended-spectrum beta lactamase (ESBL) incidence were explained by backgr

96 sistant bacteria including extended-spectrum beta-lactamase (ESBL) and carbapenem-resistant Enterobac

97 s drug pressure has driven extended-spectrum beta-lactamase (ESBL) gene acquisition and evolution in

98 la Enterobacteriaceae with extended spectrum beta-lactamase (ESBL) or fluoroquinolone resistance rose

99 he within-host dynamics of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae.

100 s had an infection with an extended spectrum beta-lactamase (ESBL) producing organism.

101 ovar Typhi isolate showing extended spectrum beta-lactamase (ESBL) production in the Democratic Repub

102 bacteriaceae suggestive of extended-spectrum beta-lactamase (ESBL) production, carbapenem-resistant E

103 h an ertapenem-susceptible extended-spectrum-beta-lactamase (ESBL)-positive phenotype were assessed f

104 e tropics annually acquire extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae (ESBL

105 s provided pivotal data on extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and C

106 jority of studies reported extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae and M

107 Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae gener

108 y uncharacterized clinical extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and K.

109 cribe two patients in whom extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli bactere

110 e increasing prevalence of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli is worr

111 n in-depth analysis of 178 extended-spectrum beta-lactamase (ESBL)-producing K. pneumoniae collected

112 c pyelonephritis caused by extended-spectrum beta-lactamase (ESBL)-producing organisms.

113 se in infections caused by extended-spectrum beta-lactamase (ESBL)-producing pathogens is recognized

114 inolone resistance (PMQR), extended-spectrum beta-lactamases (ESBL) and AmpC beta-lactamases.

115 -associated acquisition of extended-spectrum beta-lactamase- (ESBL) and carbapenemase-producing Enter

116 beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) and carbapenemases belonging to

117 ical laboratories test for extended-spectrum beta-lactamases (ESBLs) for epidemiological and infectio

118 ance and the occurrence of extended-spectrum beta-lactamases (ESBLs) modulated by farming and manager

119 n mutants and producers of extended-spectrum beta-lactamases (ESBLs), AmpCs, K1, and broad-spectrum b

120 mediated by the spread of extended-spectrum beta-lactamases (ESBLs), is a very serious medical conce

121 e boronic acid synergy test, and the metallo-beta-lactamase Etest, had specificities of >90% for dete

122 Using simulations and experiments with beta-lactamase-expressing bacteria, we found that for a

123 riptions are provided for medically relevant beta-lactamase families and various BLI combinations tha

124 ATP-dependent DNA ligase; and Exo, a metallo-beta-lactamase-family nuclease.

125 is was conducted on purified PenA1 and AmpC1 beta-lactamases from Burkholderia multivorans ATCC 17616

126 (serine beta-lactamase) but not L1 (metallo beta-lactamase) from the extensively drug resistant huma

127 ening a deep mutant library of the bla(ampC) beta-lactamase gene of Escherichia coli, we identified m

128 n gram-negative bacteria (GNB) are numerous; beta-lactamase genes carried on mobile genetic elements

129 e by current genotypic methods (negative for beta-lactamase genes or lacking predictive genotypes).

130 s were molecularly characterized to identify beta-lactamase genes.

131 y reducing the target drug concentration via beta-lactamases; however, naturally transformable bacter

132 are needed, especially compounds that resist beta-lactamase hydrolysis.

133 Serine active-site beta-lactamases hydrolyze beta-lactam antibiotics throug

134 lass of inhibitors for NDM-1 and two related beta-lactamases, IMP-1 and VIM-2, was identified.

135 ole of WhiB4 in coordinating the activity of beta-lactamase in a redox-dependent manner to tolerate A

136 notypic detection of the OXA-48-type class D beta-lactamases in Enterobacteriaceae is challenging.

137 at produce ESBLs, carbapenemases or multiple beta-lactamases in the same organism.

138 ced holomycin also strongly inhibits metallo-beta-lactamases in vitro, major contributors to clinical

139 nalogues able to inhibit clinically-relevant beta-lactamases, including AmpC, Extended-Spectrum BLs (

140 ia is commonly associated with production of beta-lactamases, including extended-spectrum beta-lactam

141 entify susceptibility to 2 newer beta-lactam/beta-lactamase inhibitor (BL-BLI) combinations, ceftazid

142 NDM is impervious to all existing beta-lactamase inhibitor (BLI) drugs, including the non-

143 nzymes, combinations of a beta-lactam with a beta-lactamase inhibitor (BLI) have been clinically succ

144 erly AAI101) is a novel penicillanic sulfone beta-lactamase inhibitor active against a wide range of

145 complex with avibactam, a diazabicyclooctane beta-lactamase inhibitor at 1.6-2.0 angstrom resolution.

146 ay crystallography and the recently approved beta-lactamase inhibitor avibactam to trap the acyl-enzy

147 c inhibitors, such as the derivatives of the beta-lactamase inhibitor avibactam, are closer to the cl

148 enem-vaborbactam (MEV) is a novel carbapenem-beta-lactamase inhibitor combination antibiotic approved

149 peracillin-tazobactam (P/T) is a beta-lactam-beta-lactamase inhibitor combination frequently used in

150 tolozane/tazobactam is a novel cephalosporin/beta-lactamase inhibitor combination that often retains

151 eftaroline, ertapenem, and novel beta-lactam-beta-lactamase inhibitor combinations from January 2017

152 y with respect to empirical therapy with new beta-lactamase inhibitor combinations such as ceftazidim

153 duced by various beta-lactams or beta-lactam-beta-lactamase inhibitor combinations.

154 plications, particularly for new beta-lactam/beta-lactamase inhibitor combinations.

155 ediate" analogue approach for broad-spectrum beta-lactamase inhibitor development and highlight the a

156 Despite major advances in the beta-lactamase inhibitor field, certain enzymes remain r

157 Avibactam is a non-beta-lactam beta-lactamase inhibitor for treating complicated urinar

158 e VNRX-5133 (taniborbactam) is a new type of beta-lactamase inhibitor in clinical development.

159 The beta-lactamase inhibitor relebactam can restore imipenem

160 Imipenem combined with the beta-lactamase inhibitor relebactam has broad antibacter

161 moth and mouse models shows that penicillin/beta-lactamase inhibitor susceptibility can be exploited

162 antibacterial combination consisting of the beta-lactamase inhibitor tazobactam and a fourth-generat

163 Taniborbactam is the first pan-spectrum beta-lactamase inhibitor to enter clinical development.

164 m-relebactam (an investigational beta-lactam/beta-lactamase inhibitor).

165 ycobactericidal activity in combination with beta-lactamase inhibitor, clavulanate (Clav).

166 enicillin and this activity was inhibited by beta-lactamase inhibitor, i.e. sulbactam.

167 Relebactam, a potent beta-lactamase inhibitor, in combination with Primaxin i

168 organism to amoxicillin, by repurposing the beta-lactamase inhibitor, relebactam, in combination wit

169 r amoxicillin/clavulanate, a beta-lactam and beta-lactamase inhibitor, respectively.

170 orally bioavailable diazabicyclooctane (DBO) beta-lactamase inhibitor.

171 tam), a boronic-acid-containing pan-spectrum beta-lactamase inhibitor.

172 As a pertinent example, the use of beta lactamase inhibitors in combination with beta-lacta

173 beta-Lactamase inhibitors (BLIs) can be administered in

174 CI, 1.15-2.37]) and exposure to beta-lactams/beta-lactamase inhibitors (risk ratio, 1.78 [95% CI, 1.2

175 ylpenicillin MIC >= 256 mug/ml), beta-lactam/beta-lactamase inhibitors and cephalosporins (amoxicilli

176 An overview of the most recently identified beta-lactamase inhibitors and of combination therapy is

177 Beta-lactamase inhibitors are increasingly used to count

178 Second-generation beta-lactamase inhibitors containing a diazabicyclooctan

179 tive drugs to carbapenems except beta-lactam/beta-lactamase inhibitors for the treatment of bloodstre

180 Although several new beta-lactamase inhibitors have been approved or are in c

181 to penicillins when used in combination with beta-lactamase inhibitors such as clavulanic acid.

182 This Perspective is focused on beta-lactamase inhibitors that disable the most prevalen

183 characterization of expanded-spectrum serine beta-lactamase inhibitors that potently inhibit clinical

184 A multiligand set of boronic acid (BA) beta-lactamase inhibitors was obtained using covalent mo

185 he synthesis of new beta-lactam antibiotics, beta-lactamase inhibitors, and bicyclic carbohydrate-bet

186 zabicyclooctanone and cyclic boronate serine beta-lactamase inhibitors, and of progress and strategie

187 iew is provided of the changing landscape of beta-lactamase inhibitors, exemplified by the introducti

188 and avibactam are clinically deployed serine beta-lactamase inhibitors, important as a defence agains

189 ephalosporins, fluoroquinolones, beta-lactam/beta-lactamase inhibitors, multidrug resistant strains a

190 ztreonam-like beta-lactams plus nonclassical beta-lactamase inhibitors, particularly avibactam-like a

191 lactam antibiotics in a manner distinct from beta-lactamase inhibitors.

192 mechanism distinct from that of traditional beta-lactamase inhibitors.

193 incipal bacterial resistance mechanisms: (i) beta-lactamase inhibitors; (ii) outer membrane permeabil

194 A second focus is beta-lactamase interactions with carbapenems, as carbape

195 Expression of beta-lactamase is the single most prevalent determinant

196 ic acid (BZB), a nanomolar inhibitor of AmpC beta-lactamase (K i = 27 nM), we have identified and cha

197 We expressed a MBLAC2 human beta-lactamase, known as an exosome biogenesis enzyme.

198 As we show by NMR spectroscopy, the serine beta-lactamases (KPC-2, SFC-1, CMY-10, OXA-23, and OXA-4

199 One of the ARGs, PC1 beta-lactamase may also be a mobile element that facilit

200 Metallo-beta-lactamases (MbetaLs) are the main mechanism of resi

201 a major health threat by expressing metallo-beta-lactamases (MbetaLs), enzymes able to hydrolyse the

202 ducing Enterobacteriaceae (CPE) with metallo-beta-lactamases (MbetaLs).

203 y the emergence and global spread of metallo-beta-lactamase (MBL) mediated resistance, specifically N

204 Members of the metallo-beta-lactamase (MBL) superfamily of enzymes harbor a hig

205 the antimicrobial susceptibility of metallo-beta-lactamase (MBL)-harboring Enterobacteriaceae We als

206 KPC- and OXA-type carbapenemases and metallo-beta-lactamases (MBL).

207 Metallo-beta-lactamases (MBLs) degrade a broad spectrum of beta-

208 Two recent examples are metal-dependent beta-lactamases (MBLs) from the marine organisms Novosph

209 beta-lactam antibiotics mediated by metallo-beta-lactamases (MBLs) is a growing problem.

210 ng serine beta-lactamases (SBLs) and metallo-beta-lactamases (MBLs), especially those with carbapenem

211 (SBLs) and some clinically important metallo-beta-lactamases (MBLs), including NDM-1 and VIM-1/2.

212 The worldwide dissemination of metallo-beta-lactamases (MBLs), mediating resistance to carbapen

213 , C and D) and the zinc-dependent or metallo-beta-lactamases (MBLs; class B).

214 n serine- and metal-dependent (i.e., metallo-beta-lactamases [MBLs]) carbapenemases when used in conj

215 in combination with amoxicillin to overcome beta-lactamase-mediated antibiotic resistance.

216 Following beta-lactamase-mediated opening of the beta-lactam, the

217 Understanding the nuances of AmpC beta-lactamase-mediated resistance can be challenging, e

218 ces (PADs) that can test for the presence of beta-lactamase-mediated resistance.

219 core peptide common to all 12 OXA-48 family beta-lactamase members, and YSVVPVYQEFAR, a highly speci

220 High activity against extended-spectrum beta-lactamase, methicillin-resistant S. aureus, and car

221 ntibody clone, a protease of interest, and a beta-lactamase modified by insertion of a protease cleav

222 to analyze an outbreak of New Delhi metallo-beta-lactamase (NDM)-producing K. pneumoniae that occurr

223 Infections caused by New Delhi metallo-beta-lactamase (NDM)-producing strains of multidrug-resi

224 C-1, CMY-10, OXA-23, and OXA-48) and metallo-beta-lactamases (NDM-1, VIM-1, BcII, CphA, and L1) teste

225 ctamases (VIM; n = 27) and New Delhi metallo-beta-lactamases (NDM; n = 13) tested had 100% concordanc

226 to discriminate between clinically-relevant beta-lactamases on the basis of their inhibition profile

227 Furthermore, in contrast to metallo-beta-lactamases or Klebsiella pneumoniae carbapenemases

228 em antibiotics are poorly hydrolyzed by most beta-lactamases owing to slow hydrolysis of the acyl-enz

229 es that carry carbapenem-hydrolyzing class D beta-lactamases (OXA-23, OXA-24/40 and OXA-48), as well

230 ized 10-site library (1,536 variants) of P99 beta-lactamase (P99betaL), a component of ADEPT cancer t

231 ed by two divergons that control levels of a beta-lactamase, PC1, and a penicillin-binding protein po

232 can mediate tetracycline resistance) and the beta-lactamase plasmid expressing TEM-135 are associated

233 Gram-negative bacteria expressing class A beta-lactamases pose a serious health threat due to thei

234 All isolates were beta-lactamase positive and were resistant to penicillin

235 e prevalence of intestinal Extended-spectrum Beta-lactamase producing Enterobacteriaceae (ESBL-E) car

236 Lastly, we report the presence of the AmpC beta-lactamase producing gene (CITM) in 4.56% and 3.26%

237 Clonal lineages of ESBL (Extended-Spectrum beta-Lactamase)-producing E. coli belonging to sequence

238 drug-resistant bacteria is extended-spectrum beta-lactamase-producing bacteria (ESBL-positive = ESBL(

239 antibiotic resistance to selectively target beta-lactamase-producing bacteria using our prodrug appr

240 Infections caused by extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) among

241 tream infection (BSI) with extended spectrum beta-lactamase-producing Enterobacteriaceae (EPE) in pre

242 e prevalence of intestinal extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) car

243 acquired infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) str

244 s) were rectal carriers of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E), co

245 m infections (BSIs) due to extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E).

246 Carriers of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) wh

247 axis regimens do not cover extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE).

248 f the digestive tract with extended-spectrum beta-lactamase-producing Enterobacteriaceae during ICU-h

249 acquired colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae in previousl

250 more likely to develop an extended-spectrum beta-lactamase-producing Enterobacteriaceae infection (r

251 tion to predict subsequent extended-spectrum beta-lactamase-producing Enterobacteriaceae infection we

252 Studies reporting extended-spectrum beta-lactamase-producing Enterobacteriaceae outbreaks or

253 uble disk synergy test for extended-spectrum beta-lactamase-producing Enterobacteriaceae phenotypic c

254 he ICU acquisition rate of extended-spectrum beta-lactamase-producing Enterobacteriaceae ranged from

255 colonized or infected with extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC).

256 acter baumannii (Hungary), extended-spectrum beta-lactamase-producing Escherichia coli (Spain), cefep

257 c model of transmission of extended-spectrum beta-lactamase-producing Escherichia coli in both the co

258 Extended-spectrum beta-lactamase-producing Escherichia coli isolates (ESBL

259 The emergence and global spread of beta-lactamase-producing multi-drug-resistant "superbugs

260 s had an infection with an extended spectrum beta-lactamase-producing organism.

261 t Enterococcus spp. (VRE), extended-spectrum beta-lactamase-producing organisms (ESBL), and carbapene

262 with a high prevalence of extended-spectrum beta-lactamase-producing organisms.

263 a-lactams, cephalosporins (extended-spectrum beta-lactamase-producing type SHV-12), and quinolones (p

264 illin-resistant S. aureus, extended-spectrum beta-lactamase-producing, and carbapenem-resistant Enter

265 n of multidrug resistance, extended spectrum beta-lactamase production and azithromycin resistance.

266 of PqqB are unprecedented within the metallo beta-lactamase protein family and expand the catalytic r

267 eries of 17 compounds for inhibition of five beta-lactamases representative of enzymes found in patho

268 Despite the long history of beta-lactamase research, we contend that issues includin

269 change in relative abundance of bacteria and beta-lactamase resistance genes (TEM-1) was observed ove

270 isoxazoles, a key subunit present in several beta-lactamase-resistant antibiotics.

271 allows for reassessment of beta-lactams and beta-lactamases role in humans.

272 abicyclooctanes (DBOs) are a class of serine beta-lactamase (SBL) inhibitors that use a strained urea

273 Gram-negative pathogens expressing serine beta-lactamases (SBLs) and metallo-beta-lactamases (MBLs

274 We report that VNRX-5133 inhibits serine-beta-lactamases (SBLs) and some clinically important met

275 Class A serine beta-lactamases (SBLs) are key antibiotic resistance det

276 reaction of the class D nucleophilic serine beta-lactamases (SBLs) with carbapenems also produces be

277 measures included evolutionary variation in beta-lactamases, secondary structure identity, tolerance

278 MP)-producing (n = 22) and Sao Paulo metallo-beta-lactamase (SPM)-producing (n = 14) isolates.

279 onserved in both KPC-2 and non-carbapenemase beta-lactamases, suggesting it promotes carbapenem hydro

280 it 11 (IntS11), which belongs to the metallo-beta-lactamase superfamily and is a paralog of CPSF-73,

281 vulanic acid, which suggests that penicillin/beta-lactamase susceptibility is an example of collatera

282 as been identified as hyperproduction of the beta-lactamase TEM.

283 he penicillin disk diffusion test, and three beta-lactamase tests, including the cefoxitin-induced ni

284 baxamase (SYN-004) is an orally administered beta-lactamase that was designed to be given with intrav

285 4) is one of the residues present in class A beta-lactamases that is under selective pressure due to

286 ring that is hydrolyzed by the enzyme BlaC (beta-lactamase) that is naturally expressed by M. tuberc

287 vent the protease from cleaving the modified beta-lactamase, thereby allowing the cell to survive in

288 ctam antibiotics to negate the action of the beta-lactamases, thereby restoring activity of the beta-

289 We also discuss the evolution of metallo-beta-lactamases; this illustrates how rapid antibiotic-m

290 antibiotic for the same binding site on the beta-lactamase, thus generating an evolutionary tradeoff

291 umber, and evolutionary variation in class A beta-lactamases to be the somewhat predictive of InDel f

292 ontrol over activity of any pockets found in beta-lactamases to date.

293 rected evolution of four orthologous metallo-beta-lactamases toward a new function and found that dif

294 A total of 88 New Delhi metallo-beta-lactamases-type carbapenem-resistant Escherichia co

295 We assayed a TEM-1 beta-lactamase variant and levoglucosan kinase (LGK) usi

296 on identified in several inhibitor-resistant beta-lactamase variants is associated with decreased pot

297 testing, all Verona integrin-encoded metallo-beta-lactamases (VIM; n = 27) and New Delhi metallo-beta

298 Here we show that for CTX-M-14 beta-lactamase, whereas Lys(234) is required for hydroly

299 ded on the 5' end of the RNA under study and beta-lactamase, which is able to produce a colorimetric

300 acement of the nucleophilic serine of serine beta-lactamases with cysteine yields enzymes which fragm